Gilead, MacroGenics Unite Against Hematologic Cancers in $1.7B Biobuck Deal

Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers. This comes only two months after the latter announced staff cuts.